Related references
Note: Only part of the references are listed.Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)
Silvio Danese et al.
GUT (2019)
Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease
Lyssia Belarif et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation
Kristina Scheibe et al.
GASTROENTEROLOGY (2019)
Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms
Julia Pazmandi et al.
IMMUNOLOGICAL REVIEWS (2019)
Microbial network disturbances in relapsing refractory Crohn's disease
Bahtiyar Yilmaz et al.
NATURE MEDICINE (2019)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
Bruce E. Sands et al.
JOURNAL OF CROHNS & COLITIS (2018)
A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage
Vu L. Ngo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair
Loris R. Lopetuso et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
Jason Reinglas et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease
Paul Rutgeerts et al.
GASTROENTEROLOGY (2018)
Mast cells are essential intermediaries in regulating IL-33/ST2 signaling for an immune network favorable to mucosal healing in experimentally inflamed colons
Zhigang He et al.
CELL DEATH & DISEASE (2018)
IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo
Kristina Scheibe et al.
GUT (2017)
Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients
Michael J. Rosen et al.
GASTROENTEROLOGY (2017)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
William J. Sandborn et al.
GASTROENTEROLOGY (2017)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panes et al.
GUT (2017)
IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis
Junfeng Zhu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Nathaniel R. West et al.
NATURE MEDICINE (2017)
Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
IL-33 and the intestine: The good, the bad, and the inflammatory
Zerina Hodzic et al.
CYTOKINE (2017)
Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage
Oscar Medina-Contreras et al.
JOURNAL OF IMMUNOLOGY (2016)
An increase in serum tumour necrosis factor-α during anti-tumour necrosis factor-α therapy for Crohn's disease - A paradox or a predictive index?
Piotr Eder et al.
DIGESTIVE AND LIVER DISEASE (2016)
Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency
Dror S. Shouval et al.
GASTROENTEROLOGY (2016)
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
William J. Sandborn et al.
GASTROENTEROLOGY (2016)
IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation
S. E. Russell et al.
MUCOSAL IMMUNOLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
Ulrike Billmeier et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
Julian Panes et al.
BMC GASTROENTEROLOGY (2015)
Interleukin-34 sustains inflammatory pathways in the gut
Eleonora Franze et al.
CLINICAL SCIENCE (2015)
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Walter Reinisch et al.
GUT (2015)
Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3+ Treg cell function in the intestine
O. J. Harrison et al.
MUCOSAL IMMUNOLOGY (2015)
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
Silvio Danese et al.
GUT (2015)
IL-9 and its receptor are predominantly involved in the pathogenesis of UC
Nancy Nalleweg et al.
GUT (2015)
Maintaining Intestinal Health: The Genetics and Immunology of Very Early Onset Inflammatory Bowel Disease
Judith R. Kelsen et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2015)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Absence of a role for interleukin-13 in inflammatory bowel disease
Paolo Biancheri et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease
Holm H. Uhlig et al.
GASTROENTEROLOGY (2014)
Pleiotropic functions of TNF-α in the regulation of the intestinal epithelial response to inflammation
Moritz Leppkes et al.
INTERNATIONAL IMMUNOLOGY (2014)
IL-33 Is an Unconventional Alarmin That Stimulates IL-2 Secretion by Dendritic Cells To Selectively Expand IL-33R/ST2+ Regulatory T Cells
Benjamin M. Matta et al.
JOURNAL OF IMMUNOLOGY (2014)
IL-13 Orchestrates Resolution of Chronic Intestinal Inflammation via Phosphorylation of Glycogen Synthase Kinase-3β
Stefan Fichtner-Feigl et al.
JOURNAL OF IMMUNOLOGY (2014)
Epithelial expression of interleukin-37b in inflammatory bowel disease
H. Imaeda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and-3 in Concanavalin-A-activated mesenchymal stromal cells
Alain Zgheib et al.
CYTOKINE (2013)
Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12-and IL-15-Responsive IFN-γ-Producing Cells
Anja Fuchs et al.
IMMUNITY (2013)
Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis
Clementine Perrier et al.
INFLAMMATORY BOWEL DISEASES (2013)
Incidence, Paris Classification, and Follow-up in a Nationwide Incident Cohort of Pediatric Patients With Inflammatory Bowel Disease
Katalin E. Mueller et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2013)
Human type 1 innate lymphoid cells accumulate in inflamed mucosa! tissues
Jochem H. Bernink et al.
NATURE IMMUNOLOGY (2013)
Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn's Disease
Francesca Zorzi et al.
PLOS ONE (2013)
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Mehmet Coskun et al.
PHARMACOLOGICAL RESEARCH (2013)
The Age of Gene Discovery in Very Early Onset Inflammatory Bowel Disease
Aleixo M. Muise et al.
GASTROENTEROLOGY (2012)
IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells
Margherita Coccia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Interleukin-33 Ameliorates Experimental Colitis through Promoting Th2/Foxp3+ Regulatory T-Cell Responses in Mice
Lihua Duan et al.
MOLECULAR MEDICINE (2012)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
IL-12 family cytokines: immunological playmakers
Dario A. A. Vignali et al.
NATURE IMMUNOLOGY (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation
Ashutosh Chaudhry et al.
IMMUNITY (2011)
Long-term Complications, Extraintestinal Manifestations, and Mortality in Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet et al.
INFLAMMATORY BOWEL DISEASES (2011)
Epidemiology of Pediatric Inflammatory Bowel Disease: A Systematic Review of International Trends
Eric I. Benchimol et al.
INFLAMMATORY BOWEL DISEASES (2011)
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease
Alessandra Geremia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis
Claudia Guenther et al.
NATURE (2011)
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
Carl A. Anderson et al.
NATURE GENETICS (2011)
Interleukin 37 expression protects mice from colitis
Eoin N. McNamee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Tumor Necrosis Factor α Blockade Exacerbates Murine Psoriasis-like Disease by Enhancing Th17 Function and Decreasing Expansion of Treg Cells
Hak-Ling Ma et al.
ARTHRITIS AND RHEUMATISM (2010)
Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells
Philip P. Ahern et al.
IMMUNITY (2010)
The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis
Md. Hasan Zaki et al.
IMMUNITY (2010)
Control of Intestinal Homeostasis, Colitis, and Colitis-Associated Colorectal Cancer by the Inflammatory Caspases
Jeremy Dupaul-Chicoine et al.
IMMUNITY (2010)
Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis
Lydia Durant et al.
IMMUNITY (2010)
Fontolizumab in Moderate to Severe Crohn's Disease: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2010)
Interferon-gamma-expressing Cells Are a Major Source of Interleukin-21 in Inflammatory Bowel Diseases
Massimiliano Sarra et al.
INFLAMMATORY BOWEL DISEASES (2010)
Infant colitis-it's in the genes
Erik-Oliver Glocker et al.
LANCET (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis
Luca Pastorelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Up-regulation of signal transducer and activator of transcription-3 is associated with aggravation of ulcerative colitis
Fujun Li et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2010)
IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
Sergei Grivennikov et al.
CANCER CELL (2009)
Signaling molecules: The pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer
R. Atreya et al.
CURRENT DRUG TARGETS (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
IL-21 comes of age as a regulator of effector T cells in the gut
M. C. Fantini et al.
MUCOSAL IMMUNOLOGY (2008)
IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways
Liang Zhou et al.
NATURE IMMUNOLOGY (2007)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice
Charles O. Elson et al.
GASTROENTEROLOGY (2007)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis
Marika C. Kullberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology
Holm H. Uhlig et al.
IMMUNITY (2006)
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6
D Yen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Colitis in mice lacking the common cytokine receptor γ chain is mediated by IL-6-producing CD4+ T cells
Y Kai et al.
GASTROENTEROLOGY (2005)
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α
H Mitoma et al.
GASTROENTEROLOGY (2005)
Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases
J Mudter et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
H Ito et al.
GASTROENTEROLOGY (2004)
Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form
N Corazza et al.
GASTROENTEROLOGY (2004)
NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses
T Watanabe et al.
NATURE IMMUNOLOGY (2004)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease
CY Su et al.
GASTROENTEROLOGY (2004)
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease:: A prospective cohort study
S Vermeire et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease
MF Neurath et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
TNF ligands and receptors - a matter of life and death
DJ MacEwan
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA
S Wirtz et al.
JOURNAL OF IMMUNOLOGY (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production
B Siegmund et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2001)
Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease
T Kanai et al.
GASTROENTEROLOGY (2001)
CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation
A Suzuki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Up-regulation of the IL-12 receptor β2 chain in Crohn's disease
T Parrello et al.
JOURNAL OF IMMUNOLOGY (2000)
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
B Oppmann et al.
IMMUNITY (2000)
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo
R Atreya et al.
NATURE MEDICINE (2000)
Share Paper
